TY - JOUR
KW - Betacoronavirus
KW - Buprenorphine/therapeutic use
KW - COVID-19
KW - Continuity of Patient Care/legislation & jurisprudence
KW - Coronavirus Infections/complications
KW - Humans
KW - Methadone/therapeutic use
KW - Opioid-Related Disorders/complications/therapy/virology
KW - Pandemics
KW - Pharmacists
KW - Pneumonia, Viral/complications
KW - SARS-CoV-2
KW - United States
KW - Pandemic
KW - buprenorphine
KW - Methadone
KW - opioid use disorder
KW - policy
KW - Regulations
AU - T. C. Green
AU - J. Bratberg
AU - D. S. Finnell
A1 - 
AB - We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.
AD - Opioid Policy Research Collaborative, Institute for Behavioral Health at The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachussetts, USA.; Department of Emergency Medicine and Epidemiology, The Warren Alpert School of Medicine of Brown University, Rhode Island Hospital, Providence, Rhode Island, USA.; University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA.; Johns Hopkins School of Nursing, Baltimore, Maryland, USA.
BT - Substance abuse
C5 - Education & Workforce; Opioids & Substance Use
CP - 2
CY - United States
DO - 10.1080/08897077.2020.1752351
IS - 2
JF - Substance abuse
LA - eng
M1 - Journal Article
N2 - We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.
PP - United States
PY - 2020
SN - 1547-0164; 0889-7077
SP - 147
EP - 149
EP - 
T1 - Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment
T2 - Substance abuse
TI - Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment
U1 - Education & Workforce; Opioids & Substance Use
U2 - 32314951
U3 - 10.1080/08897077.2020.1752351
VL - 41
VO - 1547-0164; 0889-7077
Y1 - 2020
ER -